Searched for
GLENMARK SHARES
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Capitalmind Flexi Cap Fund exits RIL and 2 others, hikes stake in Titan Company, MCX and 16 other stocks in AprilCapitalmind Flexi Cap Fund exited Reliance Industries, Bank of Baroda, and L&T Finance in April. The fund also increased stakes in Titan Co...
- Ahead of Market: 10 things that will decide stock market action on WednesdayNifty 50 and BSE Sensex declined amid selling in banking, auto and IT stocks. Markets remain range-bound, awaiting triggers, with analysts ...
- Actor Madhavan’s son Vedaant becomes the most-followed athlete in West Virginia. Here’s all you need to know about swimming championVedaant Madhavan, son of R. Madhavan, has become the most-followed student athlete in West Virginia, going ahead of players from more popul...
- Alkem Labs CEO Vikas Gupta may exit companyAlkem Labs, a leading Indian drug maker, is set for a top management change. Vikas Gupta, the CEO for nearly three years, is expected to de...
- Novo Nordisk’s weight-loss drug patent loss sparks a ‘gold rush’ for generic drugmakersIndia's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. ...
- US tariffs on metals and pharma: Which Indian stocks are safe and which aren't: Sudip BandyopadhyayIndian equity markets face policy risks from US tariffs and West Asia conflict. These issues impact metals and pharmaceutical sectors. Expe...
- Tariff threat ain't over yet! Sun Pharma, other pharma stocks plunge up to 6%Pharma stocks fell after reports that the Trump administration may impose tariffs—potentially up to 100%—on drugmakers not ensuring low pri...
- Two Trades for Today: A pharma major for a 6% upmove, a mid-cap healthcare stock for a gain of about 5%Our technical analysts identify select stocks that may gain momentum even in volatile markets. Here are the technical calls for today.
- Rs 12,000 crore magic pill race begins to shrink India's pot bellies. Which pharma stocks will win GLP-1 war?India's GLP-1 market is set for a massive boom. Following patent expiry, generic versions of semaglutide are launching at significantly low...
- Stock Radar: Glenmark Pharma breaks out from a range to hit fresh record high in March 2026; what should investors do?Glenmark Pharma Ltd has broken out of a 7-month consolidation on weekly charts, reaching fresh record highs. Experts suggest short-term tra...
- Glenmark shares gain 2% as firm receives $700 million upfront payment from AbbVie dealGlenmark Pharmaceuticals' shares surged following its subsidiary's $700 million upfront payment from AbbVie for an exclusive licensing agre...
- Glenmark shares in focus after recall of 15 lakh bottles of ADHD drug in USGlenmark share price: The recall affects around 14.76 lakh bottles of Atomoxetine Capsules in various strengths, produced by Glenmark Pharm...
- Glenmark Pharma to sell 7.84% stake in Glenmark Life via OFSThe stake sale will be done through the stock exchanges via an offer for sale (OFS). The decision was made at a meeting held today, and the...
- Buy Glenmark Pharma, target price Rs 560: Yes SecuritiesGlenmark Pharmaceuticals Ltd., incorporated in the year 1977, is a mid-cap company (with a market cap of Rs 14826.53 crore) operating in ph...
- Interim data from study supports Favipiravir's safety, effectiveness: GlenmarkThe study, commenced in July 2020, aimed to evaluate safety and efficacy of favipiravir in mild to moderate COVID-19 patients.
- Glenmark drops 6% as Q2 net profit declinesThe stock has nearly trebled from its March lows of Rs 168, and is up 39 per cent year-to-date.
- Glenmark buys Czech firmGlenmark pharmaceuticals on Monday announced acquisition of 90% stake in Czech firm Medicamenta to get a commercial foothold in the strateg...
Load More
